Equities

Shanghai Haohai Biological Technology Co Ltd

Shanghai Haohai Biological Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)29.00
  • Today's Change-0.40 / -1.36%
  • Shares traded190.40k
  • 1 Year change-8.04%
  • Beta0.9608
Data delayed at least 15 minutes, as of Nov 15 2024 03:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,7512,5422,907
Total Receivables, Net358421380
Total Inventory526485355
Prepaid expenses525956
Other current assets, total622515
Total current assets3,7503,5323,713
Property, plant & equipment, net1,7071,5731,419
Goodwill, net413411407
Intangibles, net575620613
Long term investments607671625
Note receivable - long term------
Other long term assets02527
Total assets7,1056,8926,950
LIABILITIES
Accounts payable555546
Accrued expenses198225174
Notes payable/short-term debt10.005.3149
Current portion long-term debt/capital leases2072917
Other current liabilities, total246197200
Total current liabilities716511487
Total long term debt191304226
Total debt408339292
Deferred income tax162164158
Minority interest367388347
Other liabilities, total191119
Total liabilities1,4551,3781,237
SHAREHOLDERS EQUITY
Common stock171174176
Additional paid-in capital2,9813,0033,091
Retained earnings (accumulated deficit)2,8172,4582,398
Treasury stock - common(248)(74)0
Unrealized gain (loss)(104)(48)61
Other equity, total321.23(13)
Total equity5,6505,5155,713
Total liabilities & shareholders' equity7,1056,8926,950
Total common shares outstanding234240246
Treasury shares - common primary issue4.624.000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.